‘The HemOnc Pulse’ Live: What Are the Unanswered Questions in ALL? | Blood Cancers Today
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.
Brittany L. Bychkovsky, MD, MSc, and Lydia Pace, MD, MPH, explain approaches to breast cancer screening and considerations with the final USPSTF screening recommendations.
Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Anita Boyapati, PhD, discussed her research on the link between soluble BCMA and both disease burden and response to BCMA-targeted therapies in this patient population.
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol in thrombocytopenic myelofibrosis.
A breast cancer breakthroughs fundraising event, where you’ll learn about the progress our dedicated physician-scientists have made for today’s patients and the discoveries they’re pursuing…
Advancements in Genitourinary Cancers: From Guidelines to Patient-Centered Care
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.